- Home
- ORGO vs OMER Comparison
ORGO vs OMER Comparison
Compare ORGO & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- OMER
- Stock Information
- Founded
- ORGO 1985
- OMER 1994
- Country
- ORGO United States
- OMER United States
- Employees
- ORGO N/A
- OMER N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- ORGO Health Care
- OMER Health Care
- Exchange
- ORGO Nasdaq
- OMER Nasdaq
- Market Cap
- ORGO 539.1M
- OMER 628.9M
- IPO Year
- ORGO N/A
- OMER 2009
- Fundamental
- Price
- ORGO $5.14
- OMER $9.65
- Analyst Decision
- ORGO Buy
- OMER Strong Buy
- Analyst Count
- ORGO 3
- OMER 5
- Target Price
- ORGO $8.00
- OMER $27.50
- AVG Volume (30 Days)
- ORGO 3.1M
- OMER 1.7M
- Earning Date
- ORGO 11-06-2025
- OMER 11-13-2025
- Dividend Yield
- ORGO N/A
- OMER N/A
- EPS Growth
- ORGO N/A
- OMER N/A
- EPS
- ORGO N/A
- OMER N/A
- Revenue
- ORGO $465,218,000.00
- OMER N/A
- Revenue This Year
- ORGO $2.51
- OMER N/A
- Revenue Next Year
- ORGO $25.45
- OMER N/A
- P/E Ratio
- ORGO N/A
- OMER N/A
- Revenue Growth
- ORGO 2.24
- OMER N/A
- 52 Week Low
- ORGO $2.61
- OMER $2.95
- 52 Week High
- ORGO $7.08
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- ORGO 50.25
- OMER 66.19
- Support Level
- ORGO $5.09
- OMER $8.04
- Resistance Level
- ORGO $5.83
- OMER $10.00
- Average True Range (ATR)
- ORGO 0.50
- OMER 0.67
- MACD
- ORGO -0.08
- OMER 0.17
- Stochastic Oscillator
- ORGO 3.02
- OMER 91.89
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.